ES2018903A6 - Un metodo de diagnosticar la presencia de una infeccion virica cronica, como el sindrome de fatiga cronica (cfs) - Google Patents

Un metodo de diagnosticar la presencia de una infeccion virica cronica, como el sindrome de fatiga cronica (cfs)

Info

Publication number
ES2018903A6
ES2018903A6 ES8902387A ES8902387A ES2018903A6 ES 2018903 A6 ES2018903 A6 ES 2018903A6 ES 8902387 A ES8902387 A ES 8902387A ES 8902387 A ES8902387 A ES 8902387A ES 2018903 A6 ES2018903 A6 ES 2018903A6
Authority
ES
Spain
Prior art keywords
chronic fatigue
fatigue syndrome
diagnosing
treating chronic
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES8902387A
Other languages
English (en)
Inventor
William A Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hem Research Inc
Original Assignee
Hem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hem Research Inc filed Critical Hem Research Inc
Publication of ES2018903A6 publication Critical patent/ES2018903A6/es
Priority to ES200301485A priority Critical patent/ES2223273A6/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

METODO DE DIAGNOSTICAR LA PRESENCIA DE UNA INFECCION VIRICA CRONICA, COMO EL SINDROME DE FATIGA CRONICA (CFS). CONSISTE EN DETERMINA LA VIA DE 2''-5'' A/RNASA L, INCLUYENDO LA MEDIDA DE LOS NIVELES DE OLIGONUCLEOTIDOS 2''-5'' A LOS LEUCOCITOS DE LA CIRCULACION SANGUINEA PERIFERICA DEL PACIENTE, Y COMPARAR ESTOS RESULTADOS CON LOS DE INDIVIDUOS SANOS. LA UTILIDAD DEL INVENTO RADICA EN QUE LOS ARN BICATENARIOS, PARTICULARMENTE LOS ARN BICATENARIOS DESAPAREADOS, CUANDO SE ADMINISTRAN EN CANTIDADES APROPIADAS, AUMENTAN EL 2''-5'' A Y NORMALIZAN LA VIA ANTIVIRICA EN PACIENTES CON SINDROME DE FATIGA CRONICA, Y MEJORAN LOS SINTOMAS CLINICOS.
ES8902387A 1988-07-07 1989-07-06 Un metodo de diagnosticar la presencia de una infeccion virica cronica, como el sindrome de fatiga cronica (cfs) Expired - Fee Related ES2018903A6 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES200301485A ES2223273A6 (es) 1988-07-07 2003-06-24 Mejora de la patente 8902387/0 para un metodo de diagnosticar la presencia de una infeccion virica cronica, como el sindrome de fatiga cronica (cfs).

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22076588A 1988-07-07 1988-07-07

Publications (1)

Publication Number Publication Date
ES2018903A6 true ES2018903A6 (es) 1991-05-16

Family

ID=22824871

Family Applications (2)

Application Number Title Priority Date Filing Date
ES89304188T Expired - Lifetime ES2066847T3 (es) 1988-07-07 1989-04-26 Diagnostico y tratamiento del sindrome de fatiga cronica.
ES8902387A Expired - Fee Related ES2018903A6 (es) 1988-07-07 1989-07-06 Un metodo de diagnosticar la presencia de una infeccion virica cronica, como el sindrome de fatiga cronica (cfs)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES89304188T Expired - Lifetime ES2066847T3 (es) 1988-07-07 1989-04-26 Diagnostico y tratamiento del sindrome de fatiga cronica.

Country Status (13)

Country Link
EP (1) EP0350151B1 (es)
CN (1) CN1056747C (es)
AT (1) ATE103493T1 (es)
AU (2) AU3781189A (es)
CA (1) CA1336685C (es)
DE (1) DE68914201T2 (es)
DK (1) DK332289A (es)
ES (2) ES2066847T3 (es)
IE (1) IE63927B1 (es)
IL (1) IL90875A (es)
NZ (1) NZ229849A (es)
PT (1) PT91094B (es)
ZA (1) ZA895143B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0495831B1 (en) * 1989-10-16 1997-01-15 Hem Pharmaceuticals Corp. Diagnosis and treatment of neuro-cognitive disorders associated with systemic immunological malfunction
GB9108085D0 (en) * 1991-04-16 1991-06-05 Scras Complexes of polyadenylic acid with polyuridylic acid
US5776690A (en) * 1996-10-07 1998-07-07 Vojdani; Aristo Detection of chronic fatigue syndrome by decreased levels of RNase L inhibitor mRNA
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
WO1999049029A1 (en) 1998-03-20 1999-09-30 Benitec Australia Ltd Control of gene expression
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
EP1229134A3 (en) 2001-01-31 2004-01-28 Nucleonics, Inc Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
US20120004290A1 (en) * 2009-03-13 2012-01-05 David Strayer Treating chronic fatigue syndrome and prolonged qt interval
EP3652542A1 (en) * 2017-07-14 2020-05-20 Protea Biopharma N.V. Methods and means for diagnosing and/or treating a fatiguing illness
EP3893893A1 (en) * 2018-12-13 2021-10-20 Aim Immunotech Inc. Methods for improving exercise tolerance in myalgic encephalomyelitis patients

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1326450C (en) * 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)
PH30882A (en) * 1987-03-03 1997-12-23 Hem Res Inc Activated Rnase L as a maker for viral infections.
AU1820388A (en) * 1987-07-17 1989-01-19 Hem Research, Inc. Double stranded rna correction of aberrant metabolic pathways associated with uncontrolled tumor cell and virus growth cycles
DE3853755T2 (de) * 1987-09-04 1995-12-14 Hem Pharma Corp Diagnose von Mangelzuständen doppelsträngiger RNS.

Also Published As

Publication number Publication date
IL90875A (en) 1994-04-12
IL90875A0 (en) 1990-02-09
DK332289A (da) 1990-01-08
CN1056747C (zh) 2000-09-27
AU3781189A (en) 1990-01-11
IE63927B1 (en) 1995-06-28
ZA895143B (en) 1991-04-24
CN1039722A (zh) 1990-02-21
IE892180L (en) 1990-01-07
EP0350151A2 (en) 1990-01-10
ATE103493T1 (de) 1994-04-15
DE68914201T2 (de) 1994-07-14
PT91094A (pt) 1990-02-08
EP0350151A3 (en) 1990-10-03
CA1336685C (en) 1995-08-15
AU6883694A (en) 1994-11-24
EP0350151B1 (en) 1994-03-30
ES2066847T3 (es) 1995-03-16
AU684288B2 (en) 1997-12-11
DK332289D0 (da) 1989-07-04
NZ229849A (en) 1997-07-27
PT91094B (pt) 1995-01-31
DE68914201D1 (de) 1994-05-05

Similar Documents

Publication Publication Date Title
Shepherd et al. Strategies for reducing coronary heart disease and desirable limits for blood lipid concentrations: guidelines of the British Hyperlipidaemia Association
Somers et al. Parasympathetic hyperresponsiveness and bradyarrhythmias during apnoea in hypertension
ES2018903A6 (es) Un metodo de diagnosticar la presencia de una infeccion virica cronica, como el sindrome de fatiga cronica (cfs)
Berman et al. Eating attitudes in seasonal affective disorder and bulimia nervosa
Cheong et al. An epidemiological study of pityriasis rosea in Middle Road Hospital
Dawson et al. Diagnostic utility of autonomic measures for major depressive disorders
Jung et al. Paroxysmal choreoathetosis: report of Chinese cases
Ostfeld et al. Personality factors and pressor mechanisms in renal and essential hypertension
Smallridge et al. Rest and exercise left ventricular ejection fraction before and after therapy in young adults with hyperthyroidism and hypothyroidism
Garruti et al. Links between metabolic syndrome and cardiovascular autonomic dysfunction
Bambery et al. Anorexia nervosa in a patient with systemic lupus erythematosus
HU9201196D0 (en) Diagnosis and treatment of neuro-cognitive disorders associated with systemic immunological malfunction
Soutou et al. Myeloproliferative disorder therapy: assessment and management of adverse events—a dermatologist's perspective
Pohl et al. Lactate and isoproterenol infusions in bulimic patients
Weinstein et al. A Case of the Forgotten Thyroid: The Sequelae of Chronic Untreated Hypothyroidism
Jumbo Autoimmunity Evaluation
Mintz et al. " Cognitive-behavioral therapy in geriatric depression": Reply to Riskind, Beck, and Steer.
Yu et al. Study on relation of kidney-deficiency with hearing damage and serum trace elements in patients with chronic nephropathy
Richards Research into aging: exploding myths
许以平 et al. RELATIONSHIP BETWEEN IgD AND ASTHMA
Stamler et al. Coronary proneness and approaches to preventing heart attacks
Ashkinazi Functional deficiency of erythrocyte thromboplastin factor
Lukas The Effects of TM on Concurrent Heart Rate, Peripheral Blood Pulse Volume, and the Alpha Wave Frequency.
Karnad et al. Diuretic treatment in decompensated cirrhosis and congestive heart failure: Effect of posture
Roath Managing Raynaud's phenomenon: Author's reply

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20100315